ATTD 2025: Technological Innovation and Collaborative Care at the Forefront in Amsterdam
The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) was held in Amsterdam from 19–22 March, drawing global healthcare professionals, researchers and innovators together to share the latest in diabetes care. For nursing professionals, especially those specialising in diabetes, the conference offered vital insight into the evolving landscape of care and the crucial role we play in delivering it.
Technology updates
Control-IQ+: Supporting People with Type 2 Diabetes
Tandem Diabetes Care introduced Control-IQ+, a new algorithm developed for automated insulin delivery in people with both type 1 and type 2 diabetes. Clinical trial data revealed significant improvements in glycaemic outcomes, with a 24% increase in time-in-range and an average 0.9% drop in HbA1c—demonstrating potential benefits for nurses supporting people with type 2 diabetes transitioning to tech-assisted therapies.
Dexcom G7 (15-Day Sensor)
The extended-wear G7 continuous glucose monitor was also unveiled, now offering up to 15 days of use. Improved sensor accuracy and reduced need for changes may aid in improving adherence and easing the patient burden—areas where nurses play a key role through education and ongoing support.
Expanding Access with Omnipod 5
The Omnipod 5 closed-loop system showed positive results in individuals moving from multiple daily injections. Participants reduced their HbA1c from 8.1% to 7.2%, and increased time-in-range from 39% to 65%. Diabetes nurses supporting transitions to technology-based therapies will find this development especially relevant to patient education and empowerment.
The Bihormonal Artificial Pancreas by Inreda
Inreda’s dual-hormone artificial pancreas—delivering both insulin and glucagon—demonstrated an 80% average time-in-range and a notable reduction in hypoglycaemia. This system, developed in the Netherlands, represents a shift toward fully automated care that could transform the clinical role of the nurse from manager to coach and facilitator.
Research with Direct Nursing Impact
Early Adoption of AID in Paediatrics
New evidence underlined the benefits of early automated insulin delivery (AID) in children and adolescents newly diagnosed with type 1 diabetes. Starting AID within six months was linked to lower HbA1c levels and reduced rates of severe complications—highlighting the essential advocacy role that nurses play in encouraging early access to innovative treatment.
Teplizumab and the Future of Type 1 Diabetes Therapy
Teplizumab, a novel immunotherapy for type 1 diabetes, continues to show promise. New findings suggest that it may preserve beta-cell function and improve glycaemic stability shortly after diagnosis, without increasing the risk of hypoglycaemia. Nurses can expect to play a vital role in identifying suitable candidates and supporting individuals through these treatment pathways.
Humanising Innovation: Peer Support and Recognition
A special moment at ATTD 2025 was the celebration hosted by Children with Diabetes, which honoured individuals living with diabetes for over 50 years. This moving event reaffirmed the value of long-term peer support, community connection and the importance of the human touch in a tech-forward world—something nursing professionals uniquely provide.
A Call to Nurses: Embrace the Future
ATTD 2025 reinforced that the future of diabetes care is as much about collaboration and communication as it is about innovation. As specialist nurses, we are not only implementers of new technologies but also champions for person-centred care and patient empowerment.
With these advancements, our practice will evolve—but our core role remains unchanged: to advocate, educate and care. Let’s lead the way in integrating these innovations into clinical practice, ensuring our patients benefit from both the latest science and the enduring strength of nursing.
